Related Experiment Video
Updated: Jun 27, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
[Myocardial involvement in 2494 patients with systemic lupus erythematosus]
Li-ping Qi1, Wen Zhang, Xiao-wei Yan
1Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Objective:
To investigate the clinical characteristics and related pathogenetic factors in systemic lupus erythematosus (SLE) patients with myocardial involvement.
Methods:
Clinic data and myocardial involvements were analyzed in 2494 SLE patients who admitted to our hospital from 1997 to 2007.
Results:
Myocardial involvements were seen in 13 out of 2494 SLE patients (0.52%). Dyspnea of various degrees and left ventricular systolic dysfunction are frequently found in these patients with myocardial involvements. Glucocorticoid therapy significantly increased left ventricular ejection fraction (LVEF, 37.7% +/- 5.8% vs. 40.9% +/- 7.1%, P = 0.002). Significant associations were found between anti-rRNP antibody and LVEF (r = 0.843, P = 0.001) as well as between cardiac troponin I (cTnI) and left ventricular end diastolic diameter (LVEDD) (r = 0.656, P = 0.036).
Conclusions:
Myocardium is rarely affected in patients with SLE in this cohort. Echocardiography is a valuable method for detecting cardiac abnormalities in patients with SLE. Glucocorticoid therapy could improve cardiac function in SLE patients with cardiac involvement and serological factors are related to cardiac functions.
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Myocarditis IV: Nursing Management
Cardiomyopathy I: Introduction and Classification